Altogether, overexpression of sEH at the protein and mRNA level in CNV and disease-relevant cell types indicates a role of sEH in AMD pathophysiology and provides a rationale to target these cell types for developing therapies. This evidence concerns the gene EPHX2 and age-related macular degeneration.